Actavis (ACT) Announces Retirement Of Charles M. Mayr

DUBLIN, Ireland, April 20, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that Charles M. Mayr, Chief Communications Officer, will retire from Actavis on May 15, 2015 due to health reasons.  In conjunction with Mayr's retirement, Alex Kelly, Chief Integration Officer, will assume the role of Chief Communications Officer, effective immediately.  Prior to joining Actavis in 2014, Kelly served as Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations at Forest Laboratories.

Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO

"In his nearly six years with Actavis, Charlie has been instrumental in defining and articulating our global story of evolution and success as we transformed Actavis to a Growth Pharma powerhouse," said Brent Saunders, Actavis CEO & President.  "His contributions have driven exceptional value for our Company, building critical communications bridges and relationships between Actavis and our employees, the investment community, the news media and key strategic alliances.  He leaves Actavis with an unparalleled foundation from which we will continue to communicate our compelling story to all of our audiences around the world.  I sincerely thank Charlie for his contributions and wish him well as he focuses on his health."

Mr. Mayr has served as Chief Communications Officer of Actavis since April 2012. He joined Actavis (then Watson) as Senior Vice President, Corporate Affairs in September 2009.

About Actavis

Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model Growth Pharma.  Actavis is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Actavis markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Actavis is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Actavis is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

Actavis intends to adopt a new global name Allergan pending shareholder approval in 2015.

For more information, visit Actavis' website at www.actavis.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Actavis' products; risks associated with acquisitions, mergers and joint ventures; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Annual Report on Form 10-K for the year ended December 31, 2014 and Actavis' Irish statutory financial statements and related reports for the year ended December 31, 2014, furnished with the Securities and Exchange Commission on Form 8-K on March 27, 2015. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

Investors:


Lisa DeFrancesco                 


(862) 261-7152

 


Media:


David Belian


(862) 261-8141

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.